Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748722 | 0.86 | MAPT (0.61) | MEN1KMT2AMAPTSMN1; SMN2MAOA | |
| SCHEMBL13973291 | 0.82 | NPSR1 (0.58) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL14357551 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2AMAPTSMN1; SMN2MAOA | |
| SCHEMBL162827 | 0.78 | MAPT (0.54) | MEN1KMT2AMAPTSMN1; SMN2MAOA | |
| SCHEMBL5230905 | 0.78 | HPGD (0.56) | MEN1KMT2AMAPTSMN1; SMN2MAOA | |
| SCHEMBL7757842 | 0.78 | KDM4E (0.59) | MEN1KMT2AMAPTSMN1; SMN2MAOA | |
| SCHEMBL29643318 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2AMAPTSMN1; SMN2MAOA | |
| SCHEMBL4062158 | 0.78 | KMT2A (0.60) | MEN1KMT2ATDP1POLB | |
| SCHEMBL6420811 | 0.77 | GAA (0.63) | MEN1KMT2ATDP1MAPTSMN1; SMN2 | |
| SCHEMBL1382593 | 0.77 | KDM4E (0.60) | MEN1KMT2AMAPTSMN1; SMN2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113548948-B | Preparation method of methyl octabromoether | 宿迁联盛科技股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-113548948-A | Preparation method of methyl octabromoether | 宿迁联盛科技股份有限公司 | 2021-10-26 | — | — | CN | claimed |
| CN-116535344-B | Phthalimide preparation method of class compound | 华南理工大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-116535344-A | Preparation method of phthalimide compound | 华南理工大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-113548948-B | Preparation method of methyl octabromoether | 宿迁联盛科技股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-113548948-A | Preparation method of methyl octabromoether | 宿迁联盛科技股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | THE UNIVERSITY OF TOLEDO (US) | 2021-07-06 | — | — | US | disclosed |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2017223160-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | MEN1 3618/4885KMT2A 4561/4885TDP1 3751/4885 |
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | AIFM1, HSPE1, COX15 | MEN1 67/4885KMT2A 4789/4885TDP1 727/4885 |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | AIFM1, HSPE1, COX15 | MEN1 67/4885KMT2A 4789/4885TDP1 727/4885 |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | SLC6A7, DNPEP, PREP | MEN1 2705/4885KMT2A 2165/4885TDP1 3266/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | MEN1 3618/4885KMT2A 4561/4885TDP1 3751/4885 |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | DNPEP, ASPH, CTSC | MEN1 4377/4885KMT2A 1800/4885TDP1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.